# Venetoclax and Irinotecan in Relapsed/Refractory SCLC

> **NCT04543916** · PHASE1,PHASE2 · WITHDRAWN · sponsor: **Virginia Commonwealth University**

## Conditions studied

- Relapsed Small Cell Lung Cancer
- Refractory Small Cell Lung Carcinoma

## Interventions

- **DRUG:** Venetoclax 50 MG
- **DRUG:** Venetoclax 100 MG
- **DRUG:** Venetoclax 200 MG
- **DRUG:** Venetoclax 400
- **DRUG:** Venetoclax 600
- **DRUG:** Irinotecan 60 mg/m2
- **DRUG:** Venetoclax (RP2D)

## Key facts

- **NCT ID:** NCT04543916
- **Lead sponsor:** Virginia Commonwealth University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2021-06-30
- **Primary completion:** 2028-05-30
- **Final completion:** 2028-06-30
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** AbbVie decided to stop trial involving Venetoclax for safety measures needed
- **Last updated:** 2021-03-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04543916

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04543916, "Venetoclax and Irinotecan in Relapsed/Refractory SCLC". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04543916. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*